Lipocine (LPCN) EBIAT (2016 - 2025)
Historic EBIAT for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$3.2 million.
- Lipocine's EBIAT fell 4362.75% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year decrease of 3498.83%. This contributed to the annual value of $8352.0 for FY2024, which is 10005.11% up from last year.
- Latest data reveals that Lipocine reported EBIAT of -$3.2 million as of Q3 2025, which was down 4362.75% from -$2.2 million recorded in Q2 2025.
- Lipocine's EBIAT's 5-year high stood at $12.6 million during Q4 2021, with a 5-year trough of -$6.8 million in Q2 2021.
- In the last 5 years, Lipocine's EBIAT had a median value of -$2.6 million in 2022 and averaged -$1.8 million.
- In the last 5 years, Lipocine's EBIAT surged by 37983.26% in 2021 and then plummeted by 17606.95% in 2023.
- Quarter analysis of 5 years shows Lipocine's EBIAT stood at $12.6 million in 2021, then plummeted by 117.66% to -$2.2 million in 2022, then dropped by 2.35% to -$2.3 million in 2023, then surged by 178.09% to $1.8 million in 2024, then crashed by 278.82% to -$3.2 million in 2025.
- Its EBIAT stands at -$3.2 million for Q3 2025, versus -$2.2 million for Q2 2025 and -$1.9 million for Q1 2025.